All In Biotech

Drug Trial Radar · NCT06401538

BMB-101 in Absence Epilepsy and DEE

An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 5, 2024

Primary completion

Sep 15, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.

Conditions

  • Absence Epilepsy
  • Jeavons Syndrome
  • Dravet Syndrome
  • Lennox Gastaut Syndrome

Interventions

  • BMB-101Drug

    BMB-101 liquid administered orally twice a day for 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in seizure frequency in DEE subjectsTime frame: 10 weeks
  2. Change from baseline in the number of generalized spike-wave discharges (GSWD) on the 24 hr EEG in Absence subjects.Time frame: 6 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Royal Brisbane and Womans Hospital

    Herston, Queensland, Australia · Recruiting

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.